Drugs for Benign Prostatic hypertrophy Market Report 2026

The drugs for benign prostatic hypertrophy market size has grown steadily in recent years. It will grow from $4.55 billion in 2025 to $4.75 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to aging population growth, long-term alpha blocker usage, hospital-based urology care, availability of oral therapies, improved diagnostic tools.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increase in male life expectancy, rising healthcare access, innovation in combination drugs, expansion of outpatient urology clinics, lifestyle-related risk factors. Major trends in the forecast period include rising demand from aging male population, increased adoption of combination therapies, growth of minimally invasive drug treatments, expansion of generic bph drugs, growing awareness of early diagnosis.

The rising prevalence of prostate diseases is expected to drive the growth of the market for drugs treating benign prostatic hypertrophy (BPH) in the coming years. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ situated just below the bladder. The increase in prostate disease prevalence is largely linked to aging, along with metabolic and inflammatory factors that contribute to conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. Drugs for BPH play a key role in managing and relieving urinary symptoms associated with prostate diseases, offering benefits by reducing prostate enlargement and enhancing urine flow. For example, in August 2024, Cancer Therapy Advisor, a US-based medical information provider, reported that an estimated 299,010 new cases of prostate cancer were expected to be diagnosed in the country in 2024, representing 14.9 percent of all new cancer cases, with slightly over 35,000 deaths projected. Consequently, the growing prevalence of prostate diseases is fueling the expansion of the market for drugs targeting benign prostatic hypertrophy.

Major companies operating in the drugs for benign prostatic hypertrophy market are focusing on developing solutions with technological advancements, such as new medications for both enlarged prostate (benign prostatic hyperplasia, BPH) and erectile dysfunction, to strengthen their competitive position in the market. Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, while erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer primarily involved in paints and coatings, launched Tamsulosin + Tadalafil Capsule to broaden its product portfolio in the pharmaceutical sector, particularly in areas addressing common men's health concerns. This innovative product, Cromax, features a dual-action formulation combining Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, and Tadalafil, which enhances blood flow to the penis to support erections. This combination therapy not only provides a more convenient treatment option for men with both benign prostatic hyperplasia (BPH) and erectile dysfunction but also shows notable improvements in the International Prostate Symptom Score (IPSS).

In September 2025, Medicus Pharma Ltd., a US-based pharmaceutical company, acquired Antev Limited for an undisclosed amount. Through this acquisition, Medicus Pharma intends to strengthen its drugs for benign prostatic hypertrophy (BPH) portfolio by incorporating Antev’s established product offerings and regulatory expertise, facilitating the development and commercialization of therapies for prostate health. Antev Limited, a UK-based pharmaceutical company, specializes in urology and BPH treatments and provides drugs for benign prostatic hypertrophy.

Major companies operating in the drugs for benign prostatic hypertrophy market are Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Pfizer Inc., Ipsen S.A., Novartis International AG, Bayer AG, Merck & Co. Inc., Endo Pharmaceuticals Inc., Impax Laboratories Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Eli Lilly and Company, Bausch Health Companies Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2025. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have marginally increased the cost of imported APIs used in the manufacturing of benign prostatic hyperplasia drugs. These impacts are most evident in markets that continue to rely on cross border sourcing for pharmaceutical inputs. Rising tariff related costs have placed mild pressure on production economics and pricing strategies for BPH therapies. This has influenced procurement planning and capacity utilization decisions among manufacturers. However, tariffs are also supporting the expansion of domestic production of BPH drugs, local API manufacturing, and stronger long term supply security.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with a drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for benign prostatic hypertrophy are used to treat enlarged prostate glands by relaxing the bladder neck muscles and muscle fibers in the prostate, which makes urination easier. This condition is commonly observed in men over the age of 50.

The primary categories of medications for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other drugs. Alpha-blockers, also referred to as blockers or adrenoreceptor antagonists, are a class of pharmaceutical agents that function by inhibiting adrenergic receptors. The various sectors consist of hospital pharmacies, retail pharmacies, and others, and these medications are supplied through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.